Moderna's SWOT analysis: mrna stock faces challenges amid vaccine shifts

Moderna (MRNA) faces challenges amid declining COVID-19 vaccine revenues, reporting a 38% revenue decline and negative gross profit margins, though maintaining 2025 revenue guidance of $1.5-2.5 billion. Analysts project negative EPS for the next two fiscal years, highlighting profitability concerns despite cost-cutting measures aimed at reducing expenses by $1.4-1.7 billion by 2027. The company is awaiting approval for next-generation COVID-19 and RSV vaccines, and analysts view its oncology pipeline as a promising area for long-term growth.

Analysis

Moderna (MRNA) is navigating a significant transition marked by declining COVID-19 vaccine revenues, which fell 38.35% in the last twelve months to $3.18 billion, with Q1 2025 revenue reported at $108 million. Despite maintaining its 2025 revenue guidance of $1.5-2.5 billion, analysts project continued sales decline and negative earnings per share for the next two fiscal years (FY1: -9.97, FY2: -6.17), exacerbated by a weak gross profit margin of -82.37%. Competitive pressures are evident, with Moderna's Q1 2025 US Spikevax sales of $29 million lagging considerably behind Pfizer's Comirnaty sales of $229 million. In response, Moderna has implemented aggressive cost-cutting measures, targeting $1.4-1.7 billion in expense reductions by 2027, aiming for break-even by 2028; however, the company is rapidly burning through cash, with a negative free cash flow of $4 billion over the last twelve months. The company's future prospects heavily rely on its product pipeline, which includes anticipated US approval decisions for its next-generation COVID-19 and RSV vaccines by mid-2025, and upcoming Phase 3 data for its standalone flu and cytomegalovirus vaccines. The oncology vaccine platform is highlighted as a key area for potential long-term growth, although the overall sentiment remains strongly negative, reflecting substantial near-term challenges.

Key Decisions for Investors

• Closely monitor the mid-2025 PDUFA dates for Moderna's next-generation COVID-19 and RSV vaccines, as approvals are critical near-term catalysts given the declining revenue from current products.
• Scrutinize the company's quarterly cash burn rate against its progress on the announced $1.4-1.7 billion cost reduction plan and its ability to achieve the 2028 break-even target without further diluting shareholders.
• Evaluate upcoming Phase 3 data for the flu and CMV vaccines, and any advancements in the oncology pipeline, as successful diversification beyond COVID-19 is essential for sustainable long-term growth.
• Consider the stock's significant volatility (beta 1.86) and recent 81% price decline in the context of both InvestingPro's 'undervalued' assessment and the substantial execution risks tied to pipeline commercialization and profitability.